|1.||Nałecz, Katarzyna A: 4 articles (08/2007 - 06/2002)|
|2.||Sobiesiak-Mirska, Joanna: 3 articles (03/2006 - 06/2002)|
|3.||Czeredys, Magdalena: 2 articles (03/2013 - 08/2007)|
|4.||Hersberger, Martin: 1 article (01/2014)|
|5.||Pérez-Valero, Vidal: 1 article (01/2014)|
|6.||Lemieux, Hélène: 1 article (01/2014)|
|7.||Rodríguez-Espinosa, Manuel: 1 article (01/2014)|
|8.||Ruiz-Escalera, Juan: 1 article (01/2014)|
|9.||Yahyaoui, Raquel: 1 article (01/2014)|
|10.||Dayaldasani, Anita: 1 article (01/2014)|
11/01/1989 - "We examined in isolated superfused guinea-pig papillary muscle whether palmitoylcarnitine caused electrophysiological derangements similar to those caused by anoxia, and whether l-carnitine was similarly effective in improving membrane potential characteristics in both cases. "
01/01/2010 - "Following recovery from hypoxia, concentrations of propionylcarnitine, palmitoylcarnitine, stearoylcarnitine were increased in neonatal hearts, while oleylcarnitine and linoleylcarnitine concentrations were increased in neonatal plasma. "
11/01/1989 - "It is concluded from these results that acylcarnitines such as palmitoylcarnitine, the accumulation of which has been thought to inhibit oxidative phosphorylation in ischemic heart, induce electrophysiological derangements quite similar to those found under anoxia, and that the application of l-carnitine is an effective solution to improve the electrophysiological derangements."
11/01/1989 - "Effects of l-carnitine on membrane potential derangements induced by palmitoylcarnitine and anoxia in isolated superfused guinea-pig papillary muscle."
06/01/2008 - "Chronic hypoxia decreased basal (V(0), -31% with pamitoylCoA + carnitine and -21% with palmitoylcarnitine, P < 0.05) and maximal (V(max), -31% with pamitoylCoA + carnitine, P < 0.05) respiration rates, hydroxyacylCoA dehydrogenase activity (-48%, P < 0.05), mCPT-1 activity index (-34%, P < 0.05) and mCPT-1 protein content (-34%, P < 0.05). "
06/01/1995 - "This study was performed to determine whether long-chain acylcarnitines, specifically palmitoylcarnitine, could account for the increase in intracellular Na+ ([Na+]i) during ischemia eliciting a secondary increase in intracellular Ca2+ ([Ca2+]i). "
01/01/1996 - "This was associated with a moderation of the ischemia-induced decrease in mitochondrial palmitoylcarnitine oxidation. "
11/01/1992 - "Decreased palmitoylcarnitine-carnitine exchange following ischemia resulted from decreased matrix carnitine rather than decreased translocase activity. "
07/01/1989 - "Effects of lysophosphatidylcholine and palmitylcarnitine--lipid metabolites produced in ischemia--on porcine coronary and rabbit femoral arteries."
10/30/1985 - "Perfusion of rat hearts according to the Langendorff technique with micromolar concentrations of palmitoylcarnitine or millimolar concentrations of phenylmethylsulfonyl fluoride protect the heart from deterioration by reperfusion after total-ischemia. "
12/01/1986 - "Also, palmitoylcarnitine inhibited skin tumor promotion by TPA; application of 3 mumol of palmitoylcarnitine in conjunction with each promotional treatment with 10 nmol of TPA to the initiated skin of female CD-1 mice inhibited tumor formation. "
04/01/1986 - "In addition, palmitoylcarnitine markedly inhibited skin tumor promotion induced by TPA. "
04/01/1986 - "Therefore, it seems unlikely that the potent anti-tumor-promoting action of palmitoylcarnitine, which is shown in the present study, is explained solely by its effect on protein kinase C."
04/01/1986 - "Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and epidermal ornithine decarboxylase activity in mouse skin by palmitoylcarnitine."
02/01/2013 - "We identified a heterogeneous distribution of palmitoylcarnitine, stearoylcarnitine, PC(16:0/22:1), and SM(d18:1/16:0) sodium adduct, which colocalized primarily with hypoxic tumor regions. "
04/01/2006 - "The structure of CPT-2 in complex with the generic CPT inhibitor ST1326 ([R]-N-[tetradecylcarbamoyl]-aminocarnitine), a substrate analog mimicking palmitoylcarnitine and currently in clinical trials for diabetes mellitus treatment, was solved at 2.5 A resolution. "
01/01/2003 - "In comparison to the controls, diabetes mellitus patients excrete more long-chain carnitine esters ranging from dodecanoyl to palmitoylcarnitine. "
|5.||Colonic Neoplasms (Colon Cancer)
06/01/2005 - "In the present study we show that a supply of palmitoylcarnitine together with L-carnitine potently induces apoptosis in HT-29 human colon cancer cells as a consequence of accelerated fatty acid oxidation. "
12/01/2005 - "Increased mitochondrial palmitoylcarnitine/carnitine countertransport by flavone causes oxidative stress and apoptosis in colon cancer cells."
|2.||Protein Kinase C
|3.||Succinic Acid (Succinate)
|4.||Pyruvic Acid (Pyruvate)
|5.||Adenosine Triphosphate (ATP)
|6.||Adenosine Diphosphate (ADP)
|8.||malic acid (malate)
|10.||Palmitoyl Coenzyme A (Palmitoyl CoA)